RXDX-106 (CEP-40783) is primarily investigated for its potential in cancer therapy, particularly targeting specific signaling pathways involved in tumor growth and survival. It functions as a potent inhibitor of AXL and c-MET receptor tyrosine kinases, which play critical roles in cancer progression, metastasis, and resistance to treatment. This compound is being explored for its efficacy in treating various solid tumors, including non-small cell lung cancer, renal cell carcinoma, and other malignancies where AXL and c-MET are overexpressed or dysregulated. Preclinical studies have shown promise in reducing tumor growth and enhancing the effects of other anticancer therapies. Clinical trials are ongoing to evaluate its safety, tolerability, and therapeutic potential in human patients, with a focus on identifying optimal dosing and combination strategies with existing treatments.